Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

121. Initial experience with the bispecific anti-CEA anti-CD3 antibody and its expected impact on future treatment for patients with colorectal cancer Full Text available with Trip Pro

Initial experience with the bispecific anti-CEA anti-CD3 antibody and its expected impact on future treatment for patients with colorectal cancer 29862052 2018 06 04 2059-7029 3 4 2018 ESMO open ESMO Open Initial experience with the bispecific anti-CEA anti-CD3 antibody and its expected impact on future treatment for patients with colorectal cancer. e000377 10.1136/esmoopen-2018-000377 Argiles Guillem G Gastrointestinal Malignancies Program, Vall d'Hebron University Hospital, Barcelona, Spain (...) . eng Journal Article 2018 05 20 England ESMO Open 101690685 2059-7029 colorectal cancer Competing interests: None declared. 2018 6 5 6 0 2018 6 5 6 0 2018 6 5 6 1 epublish 29862052 10.1136/esmoopen-2018-000377 esmoopen-2018-000377 PMC5976108

2018 ESMO open

122. Lysyl oxidase: A colorectal cancer biomarker of lung and hepatic metastasis Full Text available with Trip Pro

Lysyl oxidase: A colorectal cancer biomarker of lung and hepatic metastasis Colorectal cancer (CRC) is a common and lethal disease in which distant metastasis remains the primary cause of death. Paradoxical roles of LOX have been reported in CRC, and the intracellular function of LOX has also recently been determined. Correlations of LOX expression and its intracellular localization with clinicopathological features in CRC patients remain largely unknown. The aim of the present study (...) nuclear localization was found to correlate with lung/hepatic metastasis, elevated serum carcinoembryonic antigen concentration, and mucinous tumor type (P < 0.05). Nuclear LOX expression was found to be associated with poor overall and disease-free survival (P < 0.05), and postoperative lung/hepatic metastasis (P < 0.05). Knockdown of YAP or TEAD4 induced downregulation of LOX expression.LOX nuclear localization was significantly associated with poor survival in patients with CRC. Nuclear LOX

2018 Thoracic cancer

123. Interaction between Host MicroRNAs and the Gut Microbiota in Colorectal Cancer Full Text available with Trip Pro

Interaction between Host MicroRNAs and the Gut Microbiota in Colorectal Cancer Although variation in gut microbiome composition has been linked with colorectal cancer (CRC), the factors that mediate the interactions between CRC tumors and the microbiome are poorly understood. MicroRNAs (miRNAs) are known to regulate CRC progression and are associated with patient survival outcomes. In addition, recent studies suggested that host miRNAs can also regulate bacterial growth and influence (...) studies have found an association between colorectal cancer (CRC) and the gut microbiota. One potential mechanism by which the microbiota can influence host physiology is through affecting gene expression in host cells. MicroRNAs (miRNAs) are small noncoding RNA molecules that can regulate gene expression and have important roles in cancer development. Here, we investigated the link between the gut microbiota and the expression of miRNA in CRC. We found that dozens of miRNAs are differentially

2018 mSystems

124. Association of Colonoscopy Adenoma Findings With Long-term Colorectal Cancer Incidence. Full Text available with Trip Pro

Association of Colonoscopy Adenoma Findings With Long-term Colorectal Cancer Incidence. Individuals with adenomatous polyps are advised to undergo repeated colonoscopy surveillance to prevent subsequent colorectal cancer (CRC), but the relationship between adenomas at colonoscopy and long-term CRC incidence is unclear.To compare long-term CRC incidence by colonoscopy adenoma findings.Multicenter, prospective cohort study of participants in the Prostate, Lung, Colorectal, and Ovarian (PLCO (...) -2.7], P = .68).Over a median of 13 years of follow-up, participants with an advanced adenoma at diagnostic colonoscopy prompted by a positive flexible sigmoidoscopy result were at significantly increased risk of developing colorectal cancer compared with those with no adenoma. Identification of nonadvanced adenoma may not be associated with increased colorectal cancer risk.clinicaltrials.gov Identifier: NCT00002540.

2018 JAMA Controlled trial quality: predicted high

125. Differential diagnosis of gastrointestinal stromal tumor by histopathology and immunohistochemistry Full Text available with Trip Pro

Differential diagnosis of gastrointestinal stromal tumor by histopathology and immunohistochemistry Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors in the gastrointestinal (GI) tract. GISTs account for approximately 80% of the clinically relevant GI mesenchymal tumors. Although most GISTs show spindle cell morphology, 10-15% of GISTs show pure epithelioid configuration. Therefore, not only spindle cell tumors but also epithelioid cell ones developing in the GI (...) cell morphology, consist of approximately 10% of the clinically relevant GI mesenchymal tumors and are almost positive for desmin and negative for KIT and S100 protein. Schwannomas which nearly always show the spindle cell pattern, comprise up to 5% of the GI mesenchymal tumors, and almost all of them are positive for S100 protein and negative for KIT and desmin. Thus, most GI mesenchymal tumors are differentially diagnosed by immunohistochemistry (IHC) of KIT, desmin and S100 protein. However

2018 Translational gastroenterology and hepatology

126. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. (Abstract)

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. The estimation of risk of recurrence for patients with colon carcinoma must be improved. A robust immune score quantification is needed to introduce immune parameters into cancer classification. The aim of the study was to assess the prognostic value of total tumour-infiltrating T-cell counts and cytotoxic tumour-infiltrating T-cells counts with the consensus (...) Immunoscore assay in patients with stage I-III colon cancer.An international consortium of 14 centres in 13 countries, led by the Society for Immunotherapy of Cancer, assessed the Immunoscore assay in patients with TNM stage I-III colon cancer. Patients were randomly assigned to a training set, an internal validation set, or an external validation set. Paraffin sections of the colon tumour and invasive margin from each patient were processed by immunohistochemistry, and the densities of CD3+ and cytotoxic

2018 Lancet

127. Should rectal cancer located 10-15 cm from the anal verge be defined as colon cancer. Full Text available with Trip Pro

Should rectal cancer located 10-15 cm from the anal verge be defined as colon cancer. 27836884 2018 05 08 2018 05 08 1569-8041 28 3 2017 03 01 Annals of oncology : official journal of the European Society for Medical Oncology Ann. Oncol. Should rectal cancer located 10-15 cm from the anal verge be defined as colon cancer. 664-665 10.1093/annonc/mdw620 Swets M M Departments of Surgery; 2Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands. Breugom A J AJ Departments (...) Colonic Neoplasms classification diagnosis pathology therapy Humans Neoadjuvant Therapy Neoplasm Staging Rectal Neoplasms classification diagnosis pathology therapy 2016 11 12 6 0 2018 5 9 6 0 2016 11 13 6 0 ppublish 27836884 mdw620 10.1093/annonc/mdw620

2018 Annals of oncology : official journal of the European Society for Medical Oncology Controlled trial quality: uncertain

128. Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer Full Text available with Trip Pro

Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer The anti-epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab in combination with chemotherapy is a standard of care in the first-line treatment of RAS wild-type (wt) metastatic colorectal cancer (mCRC) and has demonstrated efficacy in later lines. Progressive disease (PD) occurs when tumours develop resistance to a therapy, although controversy remains about whether PD (...) because they have probably developed resistance to the chemotherapeutic agents rather than the biologic component of the regimen. Conversely, patients whose disease progresses on cetuximab-based therapy due to drug-selected clonal expansion of RAS-mutant tumour cells may regain sensitivity to cetuximab following a defined break from anti-EGFR therapy. Looking to the future, we propose that RAS status determination at disease progression by liquid, needle or excisional biopsy may identify patients

2018 ESMO open

129. Effect of public reporting of surgeons' outcomes on patient selection, "gaming," and mortality in colorectal cancer surgery in England: population based cohort study. Full Text available with Trip Pro

to 31 March 2015 included in the National Bowel Cancer Audit.Public reporting of surgeon specific 90 day mortality in elective colorectal cancer surgery in England introduced in June 2013.Proportion of patients with colorectal cancer who had an elective major resection, predicted 90 day mortality based on characteristics of patients and tumours, and observed 90 day mortality adjusted for differences in characteristics of patients and tumours, comparing patients who had surgery between April 2011 (...) Effect of public reporting of surgeons' outcomes on patient selection, "gaming," and mortality in colorectal cancer surgery in England: population based cohort study. To determine the effect of surgeon specific outcome reporting in colorectal cancer surgery on risk averse clinical practice, "gaming" of clinical data, and 90 day postoperative mortality.National cohort study.English National Health Service hospital trusts.111 431 patients diagnosed as having colorectal cancer from 1 April 2011

2018 BMJ

130. Comparison of prognostic models to predict the occurrence of colorectal cancer in asymptomatic individuals: a systematic literature review and external validation in the EPIC and UK Biobank prospective cohort studies Full Text available with Trip Pro

Comparison of prognostic models to predict the occurrence of colorectal cancer in asymptomatic individuals: a systematic literature review and external validation in the EPIC and UK Biobank prospective cohort studies To systematically identify and validate published colorectal cancer risk prediction models that do not require invasive testing in two large population-based prospective cohorts.Models were identified through an update of a published systematic review and validated in the European (...) Prospective Investigation into Cancer and Nutrition (EPIC) and the UK Biobank. The performance of the models to predict the occurrence of colorectal cancer within 5 or 10 years after study enrolment was assessed by discrimination (C-statistic) and calibration (plots of observed vs predicted probability).The systematic review and its update identified 16 models from 8 publications (8 colorectal, 5 colon and 3 rectal). The number of participants included in each model validation ranged from 41 587 to 396

2018 EvidenceUpdates

131. Colorectal Cancer Screening

35% of polyps 6 to 10 mm and 17% of polyps >11 mm [58]. A retrospective study evaluated the diagnostic yield of DCBE examinations performed for colorectal cancer screening in average-risk individuals >50 years of age [59]. The diagnostic yield was 5.1% for neoplastic lesions =10 mm and 6.2% for advanced neoplastic lesions, regardless of size. These diagnostic yields fall within the lower range of those reported for screening colonoscopy (5.0% to 9.5% for colonic neoplasms =10 mm [60-62] and 4.6 (...) % to 11.7% for advanced colonic neoplasms, regardless of size [60,62,63]). Additional data on the effectiveness of the DCBE for detecting colorectal cancer comes from studies in which the imaging history of patients with colorectal cancer was reviewed. In many of these studies, the risk level of patients undergoing DCBE was not reported. Based on this methodology, the sensitivity of DCBE ranges from 75% to 95% [64-66]. This correlates with a large, population-based study that found the overall rate

2018 American College of Radiology

132. Combination drug development in BRAF mutant colorectal cancer Full Text available with Trip Pro

Combination drug development in BRAF mutant colorectal cancer 29854866 2018 11 14 2331-4737 5 3-4 2018 Mar Oncoscience Oncoscience Combination drug development in BRAF mutant colorectal cancer. 51-53 10.18632/oncoscience.399 Lam Michael M Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), and the Department of Thoracic/Head and Neck Medical Oncology; Khalifa Institute for Personalized Cancer Therapy;The Institute for Applied Cancer Science, The University (...) of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), and the Department of Thoracic/Head and Neck Medical Oncology; Khalifa Institute for Personalized Cancer Therapy;The Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 455, Houston, Texas 77030, USA. eng Editorial 2018 04 29 United States Oncoscience 101636666 2331-4737 BRAF mutant colorectal cancer ERK MEK combinations resistance CONFLICTS OF INTEREST The authors declare

2018 Oncoscience

133. Targeting parallel bypass signaling to combat adaptive resistance to BRAF inhibition in colorectal cancer Full Text available with Trip Pro

Targeting parallel bypass signaling to combat adaptive resistance to BRAF inhibition in colorectal cancer 29854868 2018 11 14 2331-4737 5 3-4 2018 Mar Oncoscience Oncoscience Targeting parallel bypass signaling to combat adaptive resistance to BRAF inhibition in colorectal cancer. 57-58 10.18632/oncoscience.401 Gao Chenxi C Department of Pharmacology and Chemical Biology, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA. Hu Jing J Department (...) of Pharmacology and Chemical Biology, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA. eng Editorial 2018 04 29 United States Oncoscience 101636666 2331-4737 BRAF CRC FAK resistance the Wnt/b-catenin pathway CONFLICTS OF INTEREST The authors declare no potential conflicts of interest. 2018 04 16 2018 04 16 2018 6 2 6 0 2018 6 2 6 0 2018 6 2 6 1 epublish 29854868 10.18632/oncoscience.401 401 PMC5978442 Sci Signal. 2012 Jan 10;5(206):ra3 22234612 Proc Natl Acad

2018 Oncoscience

134. The safety and clinical efficacy of recombinant human granulocyte colony stimulating factor injection for colon cancer patients undergoing chemotherapy. Full Text available with Trip Pro

The safety and clinical efficacy of recombinant human granulocyte colony stimulating factor injection for colon cancer patients undergoing chemotherapy. The present study was designed to evaluate safety and efficacy of recombinant human granulocyte colony stimulating factor (G-CSF) injection and whether this regimen could reduce the incidence of adverse events caused by chemotherapy.A total of 100 patients with colon cancer who were treated with chemotherapy in our hospital from January 2011 (...) , the incidence of liver dysfunction in the treatment group was lower than that of the control group, without statistical significance. The incidence of myalgia in the treatment was higher than that of the control group without statistical significance.The present study indicated that G-CSF injection after chemotherapy is safe and effective for preventing adverse events in colon cancer patients with chemotherapy.

2018 Revista da Associacao Medica Brasileira (1992) Controlled trial quality: uncertain

135. Perspectives on the evolving state of the art management of gastrointestinal stromal tumours Full Text available with Trip Pro

Perspectives on the evolving state of the art management of gastrointestinal stromal tumours Gastrointestinal stromal tumours (GISTs) represent a very exciting tumour entity for the medical oncologist. There has been extensive clinical and preclinical research dissecting the natural behaviour, molecular landscape and therapeutic responsiveness of this rare mesenchymal tumour. Various molecular subtypes of GIST have a differing prognostic and predictive relevance in the state of the art (...) management of the disease. Emerging mature clinical trial data gathered over the last one and half decade provided substantial molecular profiling information in understanding the success and eventual failure of treatment. In our review of the most relevant literature we aim to guide the clinician in tailoring neoadjuvant, adjuvant and palliative treatment of GIST alongside the different, now well established molecular subgroups of GISTs.

2018 Translational gastroenterology and hepatology

136. Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data se Full Text available with Trip Pro

Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data se In the RAISE trial, ramucirumab+leucovorin/fluorouracil/irinotecan (FOLFIRI) improved the median overall survival (mOS) of patients with previously treated metastatic colorectal cancer versus patients treated with placebo+FOLFIRI but had

2018 ESMO open Controlled trial quality: uncertain

137. Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer Full Text available with Trip Pro

Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer The International Duration Evaluation of Adjuvant chemotherapy project investigated whether a shorter duration of oxaliplatin-based adjuvant chemotherapy was as effective as 6 months of identical chemotherapy for resected stage III colon cancer. As part (...) of this project, we report safety data from the Japanese ACHIEVE study (JFMC47-1202-C3).ACHIEVE was an open-label, multicentre trial randomising patients with stage III colon cancer to receive 3 m or 6 m of mFOLFOX6/CAPOX after surgery. Choice of regimen was declared before randomisation by a site investigator.Between August 2012 and June 2014, 1313 patients were enrolled and, of those, 1277 were analysed for the safety analysis, with 635 in arm 6 (mFOLFOX6, n=158; CAPOX, n=477) and 642 in arm 3 (mFOLFOX6, n

2018 ESMO open Controlled trial quality: uncertain

138. Long-Term Effectiveness of Sigmoidoscopy Screening on Colorectal Cancer Incidence and Mortality in Women and Men: A Randomized Trial. Full Text available with Trip Pro

Long-Term Effectiveness of Sigmoidoscopy Screening on Colorectal Cancer Incidence and Mortality in Women and Men: A Randomized Trial. The long-term effects of sigmoidoscopy screening on colorectal cancer (CRC) incidence and mortality in women and men are unclear.To determine the effectiveness of flexible sigmoidoscopy screening after 15 years of follow-up in women and men.Randomized controlled trial. (ClinicalTrials.gov: NCT00119912).Oslo and Telemark County, Norway.Adults aged 50 to 64 years (...) in women.Norwegian government and Norwegian Cancer Society.

2018 Annals of Internal Medicine Controlled trial quality: predicted high

139. ColonFlag for identifying people at risk of colorectal cancer

methods for colorectal cancer by automatically testing people using routinely available data. It differs from other software algorithms by using machine learning techniques to improve the accuracy of predictions. Current NHS pathway or current care pathway The NHS bowel cancer screening programme offers a guaiac faecal occult blood test (gFOBT) to people aged between 60 and 74 once every 2 years. In 2015, the UK National Screening Committee recommended that the bowel cancer screening programme switch (...) . The data were taken from the KPNW tumour registry. Intervention and comparator(s) ColonFlag compared with the standard of care. ColonFlag for identifying people at risk of colorectal cancer (MIB142) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 7 of 13Key outcomes AUC=0.80±0.01. OR=34.7 (95% CI 28.9 to 40.4) for a specificity of 99%. ColonFlag was found to be more accurate at detecting right-sided CRCs than left

2018 National Institute for Health and Clinical Excellence - Advice

140. Cystic Fibrosis Colorectal Cancer Screening Consensus Recommendations Full Text available with Trip Pro

Cystic Fibrosis Colorectal Cancer Screening Consensus Recommendations Cystic Fibrosis Colorectal Cancer Screening Consensus Recommendations - Gastroenterology Email/Username: Password: Remember me Search AGA Journals Search Terms Search within Search Volume 154, Issue 3, Pages 736–745.e14 Cystic Fibrosis Colorectal Cancer Screening Consensus Recommendations x Denis Hadjiliadis Affiliations Perelman School of Medicine, University of Pennsylvania Philadelphia, Pennsylvania Correspondence Reprint (...) Institute of Oncology, Milan, Italy 5 , x Albert B. Lowenfels Affiliations New York Medical College, Valhalla, New York 6 on behalf of the x Cystic Fibrosis Colorectal Cancer Screening Task Force x Amy Leigh Braid x Amy Leigh Braid , x Joanne Cullina x Joanne Cullina , x Anne Daggett x Anne Daggett , x Aliza Fink x Aliza Fink , x Andrea Gini x Andrea Gini , x Denis Hadjiliadis x Denis Hadjiliadis , x Paul F. Harron x Paul F. Harron , x Sarah Hempstead x Sarah Hempstead , x Alexander Khoruts x Alexander

2018 Cystic Fibrosis Foundation